Introduction
Approximately 50% of the adult newly diagnosed patients with epilepsy reach seizure-freedom with the use of the first antiepileptic drug (AED), whereas only 10% respond to the second AED monotherapy. 1 If the first or second monotherapy improves control of the seizures but does not produce seizure-freedom the use of combination therapy has been advocated. 2 Combination therapy has been found to be successful in about 30% of patients. 3, 4 A recent randomized study comparing combination therapy and alternative monotherapy in patients failing on a single AED found no difference in the success rates of the therapies. 5 With the introduction of new AEDs the number of possible combinations of two or more drugs has increased dramatically. There are some combinations Seizure (2008) Summary We analyzed the effect of combination therapy on seizure frequency in all adult patients (N = 193) with focal epilepsy followed at a single institution in a cross-sectional study. One hundred and thirty-five patients were on two AEDs, of them, 37 (27%) were seizure-free, 50 patients were on three AEDs including 5 (10%) seizure-free patients ( p < 0.01 for seizure-freedom with two AEDs versus three AEDs). Thirty-five different combinations were used in patients on two AEDs and 40 combinations on patients on three drugs emphasizing the difficulties involved in evaluation of the efficacy and tolerability of specific combinations. The significant proportion of seizure-free cases (27%) on duotherapy is suggesting the usefulness of combination therapy in achieving seizure-freedom in epilepsies refractory to single drug treatment. The material in the study was not from a randomized trial and therefore the comparability of patients on different AEDs is uncertain, but on the other hand the clinical practice followed provides a natural experiment suitable for comparative, non-randomized assessment of treatment outcomes. # 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
with clinical evidence of pharmacodynamic synergism such as lamotrigine/valproate. 6 Some other combinations are judged beneficial on the bases of their complimentary mechanisms of actions without clinical data. 2 Generally, there is scarcity of evidence about effective combinations, and the new wave of polytherapy has also raised concerns of overtreatment of epilepsy. 7 We have analyzed the effect of combination therapy on seizure frequency in all adult patients with focal epilepsy, the most common refractory form of epilepsy, followed at a single institution, where the majority of therapy resistant patients of Pirkanmaa region (population of 440,000) are treated; only elderly patients and patients with mental retardation are treated elsewhere. Thus though not strictly population based our patient group probably represents the general population with refractory epilepsy.
Methods Patients
All patients with focal epilepsy followed at Tampere University Hospital 30.9.2004 were identified from the hospital patient registry using ICD-10 diagnostic codes for focal epilepsy (G40.1Â and G40.2Â). Also patients with the diagnosis number of G40.9 (Epilepsy, unspecified) were screened. The study was approved by the Ethics Committee of the Tampere University Hospital. Patients with combination therapy were included for the present study. The information of patient characteristics was obtained from the medical records. The patients were classified according to ILAE guidelines to 8 temporal lobe epilepsy, frontal lobe epilepsy, parietal/occipital lobe epilepsy, multifocal epilepsy and unclassifiable based of seizure characteristics, EEG and imaging findings, and in some patients on ictal video-EEG recordings. The etiologies were divided into remote symptomatic and cryptogenic. The mean monthly seizure frequency during the previous year was recorded; seizure-free patients did not have any seizures during the previous year. The AEDs currently used, information on doses and duration of the present regimen were registered.
Statistical methods
When comparing proportion of seizure-free patients with different number of AEDs, statistical significance was assessed using a chi-square test. Logistic regression methods were used in multivariate analyses, with persistent seizures as the outcome. Explanatory variables included gender, epilepsy type (temporal, frontal, parieto-occipital, multifocal), 
Results
Altogether 395 patients with localization-related epilepsy were identified from computerized patient database. Two hundred and two patients were on monotherapy and were excluded from this study with remaining 193 patients on combination therapy. The most common epilepsy type was temporal lobe epilepsy (42%, N = 81), 50 (26%) patients had frontal lobe epilepsy, 13 (7%) parieto-occipital epilepsy and 8 (4%) patients multifocal epilepsy (Table 1) . One hundred and thirty-five patients were on two AEDs, of them, 37 (27%) were seizure-free, 50 patients were on three AEDs including 5 (10%) seizure-free patients ( p < 0.01 for seizure-freedom with two AEDs versus three AEDs). All 8 patients on four AEDs had recurrent seizures (Table 1 ). In logistic regression analysis patients on three or four drugs had 4.5 times (95% confidence interval 1.57-12.9) higher risk for persistent seizures when compared with patients on two drugs. Table 2 Table 4 .
Discussion
The majority of patients with newly diagnosed epilepsy remain seizure-free with their first or second monotherapy, 1 and combinations of AEDs are usually prescribed in those unresponsive to monotherapy. 2 Our patients represent typical refractory focal epilepsies with high proportion of temporal lobe epilepsy and remote symptomatic etiology. In this group, seizure-freedom was achieved in a significant proportion of cases (27%) on duotherapy suggesting the usefulness of combination therapy in achieving seizure-freedom in epilepsies refractory to single drug treatment. A recent outcome study on newly diagnosed epilepsy had given a 29% response rate to two-drug combinations 3 whereas in the original 278 J. Peltola et al. report only 3% of patients achieved seizure-freedom with treatment with two drugs. 1 Only 10% of our patients with three drugs achieved seizure-freedom and none of the patients with four drugs were totally controlled.
The material in the study was not from a randomized trial and therefore the comparability of patients on different AEDs is uncertain. Furthermore, this was a cross-sectional study, so the patients had a variable history in terms of the duration of epilepsy and time since first contact to the study hospital. Homogeneity of patient population was increased by restriction of analyses to the patients with focal epilepsy treated with combination therapy at a single centre. Yet, the lack of a uniform treatment guideline actually helps the assessment of different AEDs, as the variability in the order in which AEDs are introduced improves comparability between the combinations relative to a fixed sequence of medications. Thus, the clinical practice followed provides a natural experiment suitable for comparative, non-randomized assessment of treatment outcomes.
Over the past decade 10 new AEDs have been introduced worldwide increasing the number of possible combinations substantially. In our study 35 different combinations were used in patients on two AEDs and 40 combinations on patients on three drugs emphasizing the difficulties involved in evaluation of the efficacy and tolerability of specific combinations. Several combinations in our study gave seizure-freedom and direct comparison between different combinations is difficult because new AEDs have been introduced in different time points. Lamotrigine came to market in Finland 1994, gabepentin 1995, tiagabine and topiramate 1999 Seizure-freedom with combination therapy 279 and levetiracetam 2001, whereas pregabalin and zonisamide were not licensed at the time of the investigations. In a previous study on combination therapy the regimen of lamotrigine and sodium valproate was the most common combination in patients with localization-related epilepsy achieving seizure-freedom followed by combinations of phenytoin and phenobarbital, carbamazepine and gabapentin and carbamazepine and sodium valproate. 9 In our study the most common individual combination was lamotrigine and valproate as well, but other common combinations were sodium channel blocker and topiramate or levetiracetam or tiagabine or gabapentin demonstrating usual patterns of combining a sodium channel blocker with a new AED with different mode of action (rational polytherapy). We were not able to identify any of the combinations more successful than the others.
In general, the median doses in our study were comparable to suggested target doses for most AEDs. 7 Very little known about optimal doses in combination therapy and there is a danger of using unnecessarily high doses leading to over-treatment. 7 Although only 10% of patients on three drugs achieved seizure-freedom there may be other clinical benefits obtained with combining three drugs such as changes in seizure types (disappearance of tonic-clonic seizures) and diurnal patterns of seizures.
At present the selection of combination therapy is based more on speculation than on the bases of clinical evidence. 10 In future studies the utility of combinations of two drugs versus three drugs should be evaluated, as well as the use of most common combinations in selected patient populations, for instance, frontal lobe seizures and combination of lamotrigine and valproate. 11 Also evaluation of the benefits of successive trials of new AEDs should be addressed.
